Thus, our data strongly suggest that the loss of PON2 activity in hepatocytes is associated with stimulation of de novo lipogenesis and disruption of lipolysis activity, which may lead to the exacerbation of fat accumulation in the liver of patient with NAFLD, who are predisposed to a decreased capacity of FA utilization. The gene discussed is PON2; the disease is metabolic dysfunction-associated steatotic liver disease.